The authors concluded that new oral anticoagulants were effective for patients receiving long-term anticoagulation. The benefits compared with warfarin were small and varied depending on the control achieved with warfarin. This was generally a well-conducted review and the conclusions are likely to be reliable.
To compare the benefits and harms of new oral anticoagulants versus warfarin for patients with atrial fibrillation and venous thromboembolism.
Searching
MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews were searched for relevant studies published in English from January 2001 to July 2012. The full search strategy was reported in supplementary material. Reference lists of key primary and review articles were checked. The Food and Drug Administration's Approved Drug Products website was searched for any safety issues and ClinicalTrials.gov was searched for completed unpublished studies.
Study selection
Randomised controlled trials (RCTs) that compared new oral anticoagulants with warfarin were eligible for inclusion. Participants had to be aged 18 years or older, with a history of chronic non-valvular atrial fibrillation, deep vein thromboembolism or mechanical valve replacement. Trials had to report at least one of the following outcomes: thromboembolism events that were documented radiologically and produced clinical symptoms, mortality, healthrelated quality of life, or the patient's treatment experience. Trials had to last at least six months for acute and 12 months for chronic treatment. Observational studies were eligible if they reported adverse events and participants had taken the drugs for at least one week. Due to drug safety concerns, two ximelagatran trials (no longer available) were excluded from the meta-analyses.
New oral anticoagulant drugs included direct thrombin inhibitor (dabigatran, 150mg twice daily) and factor Xa inhibitor (apixaban , 5mg twice daily, or rivaroxaban, 20mg once daily). All trials were conducted in multiple countries. The mean age of participants ranged from 50 to over 70 years, and 59% were men. The mean baseline Congestive heart failure, Hypertension, Age, Diabetes, and Stroke (CHADS 2 ) score ranged from 2.1 to 3.5 in the subgroup of patients with atrial fibrillation. The percentage of time within the target international normalised ratio (INR) ranged from 55 to 66 (median 64) in the warfarin groups. The duration of the included trials ranged from 12 months to two years.
Two reviewers were involved in study selection. Any discrepancies were resolved by discussion or by a third reviewer.
Assessment of study quality
The quality of trials was assessed by one reviewer and checked by a second, for randomisation, allocation concealment, baseline comparability, blinding, attrition, validity of outcome measures, and conflicts of interest. The quality of evidence was summarised according to Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines. Disagreements were resolved by discussion or by a third reviewer. Observational studies were all case studies and were not assessed.
Data extraction
Data to calculate relative risks and their 95% confidence intervals were extracted by one reviewer and checked by a second. Any disagreements were resolved by discussion or by a third reviewer.
Methods of synthesis
Pooled relative risks and 95% confidence intervals were calculated using a random-effects model. The primary analysis combined data for the direct thrombin inhibitor and factor Xa inhibitors presuming an effect for the class of drugs;
